These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 9339934)

  • 1. Does information from axillary dissection change treatment in clinically node-negative patients with breast cancer? An algorithm for assessment of impact of axillary dissection.
    Dees EC; Shulman LN; Souba WW; Smith BL
    Ann Surg; 1997 Sep; 226(3):279-86; discussion 286-7. PubMed ID: 9339934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer.
    Kuerer HM; Newman LA; Buzdar AU; Hunt KK; Dhingra K; Buchholz TA; Binkley SM; Ames FC; Feig BW; Ross MI; Hortobagyi GN; Singletary SE
    Am J Surg; 1998 Dec; 176(6):502-9. PubMed ID: 9926779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conservation treatment intensified with tamoxifen and CAF chemotherapy without axillary dissection for early breast cancer patients with clinically-negative axillary nodes.
    Ogawa Y; Nishioka A; Inomata T; Yokota N; Sasaki T; Terashima M; Yoshida S; Tanaka Y; Tohchika N
    Oncol Rep; 1999; 6(4):801-5. PubMed ID: 10373660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of T1a and T1b lesions.
    White RE; Vezeridis MP; Konstadoulakis M; Cole BF; Wanebo HJ; Bland KI
    J Am Coll Surg; 1996 Dec; 183(6):575-82. PubMed ID: 8957459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer.
    Kuerer HM; Newman LA; Fornage BD; Dhingra K; Hunt KK; Buzdar AU; Ames FC; Ross MI; Feig BW; Hortobagyi GN; Singletary SE
    Ann Surg Oncol; 1998 Dec; 5(8):673-80. PubMed ID: 9869512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.
    Kuerer HM; Newman LA; Buzdar AU; Dhingra K; Hunt KK; Buchholz TA; Binkley SM; Strom EA; Ames FC; Ross MI; Feig BW; McNeese MD; Hortobagyi GN; Singletary SE
    Cancer J Sci Am; 1998; 4(4):230-6. PubMed ID: 9689981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study.
    Mansour EG; Gray R; Shatila AH; Osborne CK; Tormey DC; Gilchrist KW; Cooper MR; Falkson G
    N Engl J Med; 1989 Feb; 320(8):485-90. PubMed ID: 2915651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy.
    Zurrida S; Bagnardi V; Curigliano G; Mastropasqua MG; Orecchia R; Disalvatore D; Greco M; Cataliotti L; D'Aiuto G; Talakhadze N; Goldhirsch A; Viale G
    Eur J Cancer; 2013 Oct; 49(15):3083-92. PubMed ID: 23777741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cox proportion hazard model multivariate analysis of prognosis of 1,484 axillary node-negative breast cancer patients].
    Shen K; Shen Z; Han Q
    Zhonghua Zhong Liu Za Zhi; 1997 May; 19(3):221-4. PubMed ID: 10920903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma.
    Turner RR; Ollila DW; Krasne DL; Giuliano AE
    Ann Surg; 1997 Sep; 226(3):271-6; discussion 276-8. PubMed ID: 9339933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axillary recurrence in women with a negative sentinel lymph node and no axillary dissection in breast cancer.
    Palesty JA; Foster JM; Hurd TC; Watroba N; Rezaishiraz H; Edge SB
    J Surg Oncol; 2006 Feb; 93(2):129-32. PubMed ID: 16425295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axillary lymph node dissection for breast cancer: a decision analysis of T1 lesions.
    Velanovich V
    Ann Surg Oncol; 1998 Mar; 5(2):131-9. PubMed ID: 9527266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection.
    Schulze T; Mucke J; Markwardt J; Schlag PM; Bembenek A
    J Surg Oncol; 2006 Feb; 93(2):109-19. PubMed ID: 16425290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imprint cytology of axillary lymph nodes in breast carcinoma following neoadjuvant chemotherapy.
    Jegaraj A; Kadambari D; Srinivasan K; Siddaraju N
    Acta Cytol; 2010; 54(5):685-91. PubMed ID: 20968156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy.
    Fan Z; Li J; Wang T; Xie Y; Fan T; Lin B; Ouyang T
    Breast; 2013 Dec; 22(6):1161-5. PubMed ID: 24080493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.
    Kuerer HM; Sahin AA; Hunt KK; Newman LA; Breslin TM; Ames FC; Ross MI; Buzdar AU; Hortobagyi GN; Singletary SE
    Ann Surg; 1999 Jul; 230(1):72-8. PubMed ID: 10400039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
    Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
    Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of axillary evaluation in older patients with breast cancer and associations with adjuvant therapy receipt.
    Dominici LS; Sineshaw HM; Jemal A; Lin CC; King TA; Freedman RA
    Breast Cancer Res Treat; 2018 Jan; 167(2):555-566. PubMed ID: 28990127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is information from axillary dissection relevant to patients with clinically node-negative breast cancer?
    Chua B; Ung O; Taylor R; Boyages J
    Breast J; 2003; 9(6):478-84. PubMed ID: 14616942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.